Why did the FDA remove the black-box warning

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the FDA revised the boxed warning on systemic hormone therapy because updated, more precisely analyzed evidence indicated that the original warning overstated risks for most healthy women and no longer accurately reflected what current research demonstrates about the benefit-risk balance when hormone therapy is used appropriately in suitable candidates.

What changed in the evidence

According to the WHI, the original boxed warning was added in 2002 after early data suggested higher rates of breast cancer, heart attack, and stroke in women using combined estrogen-progestin therapy. Over the following two decades, researchers re-examined that data more carefully and conducted additional studies. According to NAMS, those studies showed that:

• Age matters: Women who start hormone therapy before age 60 or within 10 years of menopause may have much lower risks than the original warning implied.
• Type and dose matter: Modern regimens use lower doses and delivery methods such as transdermal estrogen, which may carry a lower risk of clotting complications.
• Population studied mattered: According to the WHI, the trial enrolled many women who were considerably older than the typical HRT candidate, and those results may not apply to a healthy woman in her late forties or early fifties.
• Benefits were undervalued: According to ACOG, hormone therapy remains an option for hot flashes, night sweats, sleep disruption, and genitourinary symptoms, and may help maintain bone density.

According to FDA Drug Safety Communication, with this more complete picture, the FDA agreed the prior boxed warning no longer accurately reflected modern evidence and was revised accordingly. A qualified prescriber can evaluate whether hormone therapy is appropriate based on an individual patient's history and risk profile.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Why revising the warning may help women

• It reduces unnecessary fear. Women may now receive more balanced information rather than assuming hormone therapy poses the same risks for everyone.
• It supports individualized decisions. The focus is on a woman's personal health history, age, symptoms, and risk factors, as assessed by a qualified prescriber.
• It aligns with current science. According to NAMS, evidence supports that, for appropriate candidates, hormone therapy may be a suitable option when evaluated on an individual basis.

In short, according to FDA.gov, the FDA revised the boxed warning because updated research indicated that earlier concerns were overstated and did not reflect the real-world profile of modern hormone therapy when prescribed and monitored appropriately by a qualified prescriber.

Important note: FDA boxed warnings (formerly called 'black box warnings') are the FDA's most serious warning category. For systemic estrogen and estrogen/progestogen products, these warnings address endometrial cancer, cardiovascular events, breast cancer, and probable dementia. Any discussion of changes to these warnings must cite the specific FDA Drug Safety Communication or labeling revision.